Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$457.93−4.39 (-0.95%)
Close on Nov 17, 2026Market cap $247.57BP/E 26.5Yield 2.11%
Amgen total assets
Total assets on the balance sheet at the end of each period.
Amgen's total assets was $96.05B at Sep 30, 2026. For fiscal 2025 it was $90.59B, down 1.4% from the year before. Over ten years it grew 2.4% a year on average. The highest annual figure on record is $97.15B in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.59B | -1.4% |
| FY2024 | Dec 31, 2024 | $91.84B | -5.5% |
| FY2023 | Dec 31, 2023 | $97.15B | +49.2% |
| FY2022 | Dec 31, 2022 | $65.12B | +6.5% |
| FY2021 | Dec 31, 2021 | $61.17B | -2.8% |
| FY2020 | Dec 31, 2020 | $62.95B | +5.4% |
| FY2019 | Dec 31, 2019 | $59.71B | -10.1% |
| FY2018 | Dec 31, 2018 | $66.42B | -16.9% |
| FY2017 | Dec 31, 2017 | $79.95B | +3.0% |
| FY2016 | Dec 31, 2016 | $77.63B | +8.6% |
| FY2015 | Dec 31, 2015 | $71.45B | +3.5% |
| FY2014 | Dec 31, 2014 | $69.01B | +4.4% |
| FY2013 | Dec 31, 2013 | $66.13B | +21.8% |
| FY2012 | Dec 31, 2012 | $54.30B | +11.1% |
| FY2011 | Dec 31, 2011 | $48.87B | +12.4% |
| FY2010 | Dec 31, 2010 | $43.49B | +9.7% |
| FY2009 | Dec 31, 2009 | $39.63B | +8.8% |
| FY2008 | Dec 31, 2008 | $36.43B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $96.05B | +6.6% |
| Q2 FY2026 | Jun 30, 2026 | $95.64B | +8.8% |
| Q1 FY2026 | Mar 31, 2026 | $92.50B | +3.5% |
| Q4 FY2025 | Dec 31, 2025 | $90.59B | -1.4% |
| Q3 FY2025 | Sep 30, 2025 | $90.14B | -0.8% |
| Q2 FY2025 | Jun 30, 2025 | $87.90B | -3.3% |
| Q1 FY2025 | Mar 31, 2025 | $89.37B | -3.9% |
| Q4 FY2024 | Dec 31, 2024 | $91.84B | -5.5% |
| Q3 FY2024 | Sep 30, 2024 | $90.88B | +0.4% |
| Q2 FY2024 | Jun 30, 2024 | $90.91B | +0.7% |
| Q1 FY2024 | Mar 31, 2024 | $92.98B | +4.8% |
| Q4 FY2023 | Dec 31, 2023 | $97.15B | +49.2% |
| Q3 FY2023 | Sep 30, 2023 | $90.53B | +42.1% |
| Q2 FY2023 | Jun 30, 2023 | $90.27B | +52.2% |
| Q1 FY2023 | Mar 31, 2023 | $88.72B | +49.9% |
| Q4 FY2022 | Dec 31, 2022 | $65.12B | +6.5% |
| Q3 FY2022 | Sep 30, 2022 | $63.70B | -2.0% |
| Q2 FY2022 | Jun 30, 2022 | $59.29B | -5.2% |
| Q1 FY2022 | Mar 31, 2022 | $59.20B | -6.0% |
| Q4 FY2021 | Dec 31, 2021 | $61.17B | -5.4% |
| Q3 FY2021 | Sep 30, 2021 | $64.99B | -0.0% |
| Q1 FY2021 | Mar 31, 2021 | $62.54B | +1.4% |
| Q4 FY2020 | Dec 31, 2020 | $62.95B | +5.4% |
| Q3 FY2020 | Sep 30, 2020 | $64.64B | +8.9% |
| Q2 FY2020 | Jun 30, 2020 | $65.01B | +1.6% |
| Q1 FY2020 | Mar 31, 2020 | $61.67B | -7.1% |
| Q4 FY2019 | Dec 31, 2019 | $59.71B | -11.3% |
| Q2 FY2019 | Jun 30, 2019 | $59.37B | -12.3% |
| Q1 FY2019 | Mar 31, 2019 | $64.00B | -10.1% |
| Q4 FY2018 | Dec 31, 2018 | $66.42B | -16.9% |
| Q3 FY2018 | Sep 30, 2018 | $67.33B | -16.2% |
| Q2 FY2018 | Jun 30, 2018 | $67.68B | -15.0% |
| Q1 FY2018 | Mar 31, 2018 | $71.16B | -8.6% |
| Q4 FY2017 | Dec 31, 2017 | $79.95B | +3.0% |
| Q3 FY2017 | Sep 30, 2017 | $80.33B | +2.8% |
| Q2 FY2017 | Jun 30, 2017 | $79.59B | +5.5% |
| Q1 FY2017 | Mar 31, 2017 | $77.86B | – |
| Q4 FY2016 | Dec 31, 2016 | $77.63B | – |
| Q3 FY2016 | Sep 30, 2016 | $78.15B | – |
| Q2 FY2016 | Jun 30, 2016 | $75.47B | – |
See a number that looks wrong?